Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Félicien Le LouedecCatherine Alix-PanabièresThierry LafontBen C AllalRenaud GarrelLaurence DigueJoël GuigayDidier CupissolJean-Pierre DelordBenjamin LallemantMarc AlfonsiKarine AubryMartine MazelFrançois BecherFrançoise PerriardEtienne ChatelutFabienne ThomasPublished in: British journal of clinical pharmacology (2019)
Our study prospectively indicates that PS is likely a confounding factor in the relationship between cetuximab PK and PFS, patients with a poor PS having lower cetuximab plasma exposure and lower PFS.